The Oxford company of an Indian-born professor announced Tuesday that its Indian partner, the Serum Institute of India (SIIPL), has started trials of a new virus-like particle (VLP) vaccine targeting Covid-19 that has the potential to offer a revolutionary new approach to combat the pandemic. Professor Sumi Biswas, CEO and …
Read More »